In this study, we investigated the long-term treatment of dantrolene on amyloid and tau neuropathology, brain volume, and cognitive function in aged triple transgenic Alzheimer (3xTg-AD) mice. Fifteen-month old 3xTg-AD mice and wild-type controls were treated with oral dantrolene (5 mg/kg) or vehicle control twice a week for 6 months. Learning and memory were examined using the Morris Water Maze at 21 and 22 months of age. After the behavioral testing, hippocampal and cortical brain volumes were calculated with magnetic resonance imaging and motor function was evaluated using the rotorod. The amyloid burden and tau neurofibrillary tangles in the hippocampus were determined using immunohistochemistry. We found that dantrolene significantly decreased the intraneuronal amyloid accumulation by as much as 76% compared with its corresponding vehicle control, together with a trend to reduce phosphorylated tau in the hippocampus. No significant differences could be detected in hippocampal or cortical brain volume, motor function or cognition among all experimental groups, indicating that the mice were still presymptomatic for Alzheimer disease. Thus, presymptomatic and long-term dantrolene treatment significantly decreased the intraneuronal amyloid burden in aged 3xTg-AD mice before significant changes in brain volume, or cognition. and contributes to cognitive dysfunction, 25,27 then treatment with dantrolene may decrease the intraneuronal amyloid load in an AD brain as demonstrated in the current study, and contribute to the amelioration of synaptic and cognition dysfunction shown in previous studies. [9] [10] [11] The striking finding in this study is that dantrolene decreased intraneuronal accumulation in presymptomatic AD mice, suggesting it may have the potential to prevent symptomatic AD. Further studies are needed to determine if the reduction of intraneuronal amyloid accumulation by dantrolene in an AD vulnerable brain contributes to memory and learning improvement in other AD transgenic mice or in patients. In FIGURE 5 . Effects of dantrolene treatment on behavior. A and B, No significant differences were found in the average trial duration on the rotorod, which was used to assess motor function for each of the experimental groups. C-F, Learning and memory testing using the Morris Water Maze. Fifteen-month-old mice were treated with dantrolene for 6 months and their reference memory was tested at both 21 months (C) and 22 months (D) of age. There were no differences detected in the mean escape latency at either time point. E and F, No differences were found at either age in the probe test, which measured the mean of the ratio of the percent time spent in the target quadrant to the opposite quadrant when the hidden platform was removed. Experimental groups included wild-type mice treated with dantrolene (WT-DAN) (n = 14) or PBS (WT-PBS) (n = 12) and triple transgenic Alzheimer disease mice treated with dantrolene (3xTg-DAN) (n = 14) or PBS (3xTg-PBS) (n = 16). All data represent mean ± SEM and were analyzed by 2-way analysis of variance with repeated measures. DAN indicates dantrolene; PBS, phosphate buffered saline; WT, wild type.
I ntracellular calcium (Ca 2 + ) homeostasis plays an important role in neuronal growth, survival and death, and in synaptic and cognitive function. 1 Recent studies suggest that disruption of intracellular Ca 2 + homeostasis plays an important role in the neuropathology of Alzheimer disease (AD) and associated cognitive dysfunction. [2] [3] [4] In particular, abnormal Ca 2 + release from the endoplasmic reticulum (ER) via either the inositol 1,4,5-trisphosphate receptor 3, [5] [6] [7] or the ryanodine receptor (RYR) [8] [9] [10] [11] Ca 2 + channels may contribute to neuronal death, synapse, and cognitive dysfunction. The number and function of RYRs have been demonstrated to be abnormally increased not only in different brain regions of AD mice, 8, 9, 12 but also in AD patients. 13 Therefore, reversal of the overactivation of RYRs may be a new therapeutic target for the treatment of AD. 9,-11,14 Dantrolene is a known antagonist of the RYR and is used clinically to treat malignant hyperthermia, muscle spasms, and neuroleptic malignant syndrome. 14 Dantrolene has been shown to inhibit neurodegeneration induced by multiple insults, including ischemia, hypoxemia, seizures, and trauma. 14 Dantrolene has also been shown to be neuroprotective in animal models of various types of neurodegenerative diseases. 9-11,15-18, In various neuronal cultures with AD features, dantrolene also demonstrated neuroprotective effects. 14, 19 Therefore, dantrolene is theoretically a potential drug to reverse the Ca 2 + dysregulation and neuropathology in AD and restore cognitive dysfunction. In fact, our previous study has demonstrated that early and chronic treatment of dantrolene at the beginning of Ca 2 + dysregulation in triple transgenic AD (3xTg-AD) mice (with APP, presenilin-1, and tau mutations) 20 nearly abolished learning and memory loss in old age, with an associated significant reduction of amyloid burden in the brain. 10 These results were supported by 2 later studies in a different murine AD model. 9, 11 The current study further investigated whether dantrolene treatment initiated after the onset of amyloid neuropathology in aged 3xTg-AD mice, 20 could still have therapeutic effects.
METHODS

Animals
3xTg-AD mice have been demonstrated to be an adequate transgenic animal model for testing efficacy of drug treatments in AD. 10, 21 Animal protocols were approved as required by the University of Pennsylvania Institutional Animal Care and Use Committees and all mice were treated in strict accordance to the APS/NIH guidelines. 3xTg-AD mice, harboring the presinilin-1 (PS1M146V), amyloid precursor protein (APPswe), and tau (p301L) transgenes, were bred using an initial 3xTg-AD breeding pair courtesy of Dr Frank LaFerla at the University of California at Irvine, CA. The 3xTg-AD mouse model has been shown to develop both amyloid plaque and neurofibrillary tangle neuropathology and cognitive dysfunction in an age-dependent manner. [18] [19] [20] Ca 2 + dysregulation in this mouse model begins at 2 months of age, long before amyloid pathology and cognitive dysfunction are apparent. 20 Both male and female mice were used in this study and aged-matched C57BL/6 WT mice were used as controls.
Dantrolene Treatment and Experimental Groups
A 15-month-old WT and 3xTg-AD mice were fed 5 mg of dantrolene (Sigma, St Louis, MO) dissolved in 2% corn flour in 2.5 mL of phosphate buffered saline (PBS) control, twice a week, by oral gavages as described in previous studies 15, 22 for 6 months, until 21 months of age ( Fig. 1 ). Four groups of mice were included in this study: 3xTg-AD mice treated with dantrolene (3xTg-DAN); 3xTg-AD mice treated with vehicle control (3xTg-PBS); C57BL/6 WT mice treated with dantrolene (WT-DAN), or vehicle control (WT-PBS). No animals exhibited signs of toxicity and no mortality was detected in any of the groups.
Morris Water Maze (MWM) Behavioral Testing
Cognitive function was assessed in all 4 experimental groups at 21 and again at 22 months of age using the MWM tests, as we previously described. 10 The water in the 1.5-mdiameter pool was maintained at a temperature between 25 and 291C and opacified with titanium (IV) dioxide throughout the entire training and testing period to obscure the submerged 15-cm-diameter platform. After each trial, each mouse was dried and warmed before returning it to its cage. The time gap between trials was a minimum of 30 to 45 minutes. Mice were tracked with a video camera mounted above the pool, which fed images to a computer that was installed with IMAQ PCI-1407 software (National Instruments, Austin, TX). During cued training, the mice were trained to escape from the MWM for 5 days with 4 trails per day. The mice were allotted 60 seconds to find the flagged submerged platform, and then allowed to remain on the platform for 10 to 15 seconds. Those animals that did not find the platform in 60 seconds were gently guided to it, and allowed to remain there for 10 to 15 seconds before removal. There were no visual cues and the platform location was fixed and starting points were varied. Place tests were used to determine reference learning by working out the spatial relationship between distant cues and the escape platform (submerged, no flag), which remained in the same location for all place trials. The starting points were random and the time to reach the platform was recorded for each trial. The mice received 2 blocks of trials each day for 5 days. Probe tests, to determine memory retention, were conducted 1 hour after the last trial of the reference learning (place) testing. For this test, the platform was removed from the pool and the swim path was recorded for 60 seconds for each mouse. The starting location was always in the "opposite" quadrant. The ratio of the means of the percent time spent in the target quadrant compared with opposite quadrant was calculated as an indication of memory retention.
Rotorod Tests
Before the MWM, we examined the locomotor ability of all mice using the rotorod test, as described previously. 10 ( Fig. 1 ) All mice received two 60 seconds training trials on the rotorod (IITC Series 8, Life Sciences, Woodland hills, CA) at 9 rpm with a 30-minute interval between trials. The animals then underwent 3 test trials for a maximum of 120 seconds with variable speed, ranging from 4 to 40 rpm. The time spent on the rotorod was recorded for each mouse as an indicator for motor skill. The interval between trials was 60 minutes to assure that mice had enough rest between trials.
Magnetic Resonance Imaging (MRI)
In vivo MRI examinations were performed ( Fig. 1 ) on a 9.4 T horizontal bore scanner equipped with 12 cm ID 40 gauss/cm gradients and interfaced to a Direct Drive console (Agilent, Palo Alto, CA). Animals were prepared for the study by induction of general anesthesia using 2% isoflurane in oxygen delivered by a nose cone. Rectal temperature probe and respiration pillow were then mounted on the animal and the animal was positioned in a 20 mm ID quadrature RF coil (M2M, Cleveland, OH). After positioning the RF coil in the magnet, respiration and core body temperature monitoring was initiated (SAII, Stony Brook, NY). A regulated warm air source was directed over the animal while it was in the magnet to maintain core body temperature at 37 ± 11C.
After RF calibration and generation of scout images, a contiguous axial series of images spanning the central region of the brain was generated using the following acquisition parameters: TE = 20 msec, TR = 1500, field of view 16 Â16 mm, slice thickness 0.25 mm, slices = 40 to 48, matrix = 192Â192, averages = 8. Respiration gating was used during the study such that data was only acquired during the quiescent phase of the respiration cycle. The brain volume in hippocampus and cortex were quantified using MRI and compared among all experimental groups.
Immunohistochemistry and Image Analysis
Immediately after the MRI experiments, mice were euthanized ( Fig. 1 ) under 3% to 4% isoflurane by simultaneous intracardiac perfusion through the left ventricle with ice cold PBS and right atria exsanguinations. The left side of each brain was postfixed in 4% paraformaldehyde overnight at 41C before paraffin embedding. As described previously, coronal brain sections of 10 mm thickness were deparaffinized and hydrated through a series of graded alcohol steps and washed in PBS. Antigen retrieval was performed by heating in Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA) in a decloaking chamber (Biocare Medical, Concord, CA) for 2 minutes. Sections were incubated in 5% hydrogen peroxide to block endogenous peroxidase activity. Using the Vectastain mouse-on-mouse kit (Vector Laboratories), sections were blocked with mouse IgG blocking reagent for 1 hour. Slides were incubated overnight at 41C with primary antibody. Antibody 6E10 (1:600, Covance, Dedham, MA) was used to detect intracellular amyloid. 6E10 showed cross-reactivity with full-length APP, soluble APP cleaved at alpha site, C99, and A beta. Antibody AT180 (1:400, Thermo Scientific, Rockford, IL) was used for human hyperphosphorylated tau protein at the Thr231 and Ser235 residues. Negative control sections were incubated in blocking solution that did not contain primary antibody. Sections were washed in tris-buffered saline buffer (50 mM tris, 150 mM NaCl, pH 7.8), incubated in goat F(ab') 2 antimouse IgG conjugate (1:1000 for 6E10 and 1:200 for AT180) (Vector Laboratories) for 1 hour. For AT180, the sections were stained using the DAB (3, 3 0 -diaminobenzidine) horseradish peroxidase substrate and coverslipped with permount (ThermoFisher Scientific, Waltham, MA). The 6E10 sections were coverslipped with Prolong Gold antifade reagent with DAPI (cell stain) (Life Technologies, Eugene, OR).
Images were acquired and quantified using IP Lab 4.0 software (BioVision Technologies, Chester Springs, PA,) linked to an Olympus IX70 microscope (Olympus Corporation, Tokyo, Japan) equipped with a Cooke SensiCam camera (Cooke Corporation, Romulus, MI). Brain sections corresponding to the Atlas of the Developing Mouse Brain, 23 (positioned approximately 2000 to 2200 mm away from frontal pole) throughout anatomic region of interest (intermediate hippocampal CA1 region) were captured from each animal under Â4, Â 10, Â20, and Â40 magnification. Three sections were chosen from each animal and analyzed for 6E10-positive cells and plaque numbers in the hippocampal CA1 region. Two persons blinded to the treatments counted the total number of 6E10-positive cells in the hippocampal CA1 region and amyloid plague in all regions of the hippocampus on the slide, including the dentate gyrus. Similarly, the AT180-positive cells were determined in the hippocampal CA1 close to the dorsal subiculum. The areas of hippocampal CA1 region was defined according to the Atlas of the Developing Mouse Brain, 23 and the area measured using IP Lab Suite v3.7 imaging processing and analysis software (Biovision Technologies, Exton, PA). The means were calculated from 3 consecutive slides per animal.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism v5.04 software and the detailed statistical methods and animal numbers are explained in the figure legends. P < 0.05 was accepted as statistically significant.
RESULTS
Dantrolene Treatment Decreases Amyloid in Hippocampus
Intracellular amyloid, shown by 6E10-positive cells, in the hippocampal CA1 region in the 3xTg mice treated with PBS was remarkably and significantly increased compared with WT control mice (Fig. 2) . However, long-term treatment with dantrolene in these aged 3xTg-AD mice significantly reduced the intracellular amyloid by as much as 76% in the hippocampal CA1 region compared with its vehicle control (Fig. 2) . We did not detect intraneuronal amyloid in any of the WT mice and there were no identifiable extracellular amyloid plaques observed in the hippocampus of the 3xTg-AD or WT mice in any experimental group.
Effects of Dantrolene Treatment on Phosphorylated Tau Protein in Hippocampus
We detected a trend for a reduction in AT180-positive cells in the hippocampal CA1 region in the dantrolenetreated 3xTG-AD compared with 3xTg-AD controls (by as much as 30%), which did not reach statistical significance (Fig. 3B ). As expected, there were no detectable phosphorylated tau protein (AT180)-positive cells in the WT control mice treated with either dantrolene or its vehicle control (Figs. 3A, B) . Copyright r 2015 Wolters Kluwer Health, Inc. All rights reserved.
Effects of Late Dantrolene Treatment on Brain Volume
There were no significant differences in cortical or hippocampal brain volume, determined by in vivo MRI, among all experimental groups (Fig. 4 ).
Effects of Late Dantrolene Treatment on Behavior
Cognitive function was assessed using the MWM. There were no differences in motor or visual acuity in the aged 3xTg-AD or WT mice among all groups as demonstrated in the cued training (data not shown). In addition, no motor impairment was found in any of the experimental groups using the rotorod assay (Figs. 5A, B ). We could detect no significant differences in reference learning, determined by the escape latency during the place trials (Figs. 5C, D) , or in retention memory, as determined by the probe tests (Figs. 5E, F) , among all experimental groups at either 21 or 22 months of age. These results suggested that 3xTg-AD mice used in this study were presymptomatic, as learning was not impaired (Figs. 5C, D) . Synaptic dysfunction is an early event in this model and is associated with intracellular amyloid-beta accumulation in presymptomatic mice. We have found that the 3xTg-AD mice are living longer and that the AD neuropathology and cognitive decline have become delayed in progressive generations of this model.
DISCUSSION
This study demonstrates that long-term oral treatment with dantrolene in aged 3xTg-AD mice significantly decreased intraneuronal amyloid accumulation in the hippocampus. However, it is not clear whether these effects are due to an inhibition in the production of amyloid or an increased clearance of amyloid. The striking finding of this study is that dantrolene treatment starting well after the initiation of amyloid neuropathology still significantly reduced the intraneuronal amyloid load, supporting the finding from previous studies showing that dantrolene inhibited the production of pathologic amyloid 11 and subsequent aggregation. 10, 11 Studies from this 3xTg-AD mouse model and humans have found that the amyloid-beta peptide accumulates intracellularly. 20 Western blot assays in this model using 6E10 20 have shown that the intracellular accumulation of 6E10 is associated with amyloid-beta. The human tau protein is also expressed intracellularly in this model. These animals are born with both transgenes but their intracellular detection does not start until 6 to 12 months, reflective of the disease process. It is controversial as to whether extracellular amyloid plaques are the root cause of cognitive dysfunction or a side product in AD. Although some studies demonstrated the relationship between amyloid pathology and cognitive dysfunction, others have not. 24, 25 The number of plaques in AD patients does not seem to correlate with cognitive performance. In contrast, the total amyloid load may be a better measure. 26 Interestingly, intraneuronal amyloid production and aggregation may play an important role in AD neuropathology and may be a potential biomarker for the onset of AD. 20 Early intraneuronal amyloid accumulation in the hippocampus may contribute to cognitive dysfunction at a later time point in the 3xTg-AD mice. 27 In addition, amyloid accumulation may function upstream of tau, promoting tau pathology and subsequent neuronal death and/or synaptic dysfunction. 28 Amyloid oligomers may cause tau-dependent microtubule disassembly, 29 impairment of normal mitochondrial transport along microtubes, 30 dendritic microtubule severing, 31 dysregulation of the cell cycle, 32 and impairment of long-term potentiation. 33 All of these may eventually result in impaired synaptic function and subsequent cognitive dysfunction. 28 If intraneuronal amyloid accumulation plays an important role in AD neuropathology addition, it is known that ER stress plays an important role in the neuropathology of AD. 34 Abnormal Ca 2 + release from the ER, by overactivation of either InsP 3 or ryanodine receptors, contributes to ER stress, 14, 35 especially in AD. 2, 3, 35 Therefore, inhibiting the overactivation of these receptors 5, [9] [10] [11] 14 and thereby ameliorating the detrimental ER stress, may be a potential therapy for AD. Recent results from translational studies [9] [10] [11] are encouraging regarding the use of dantrolene, and other drugs that stabilize the intracellular Ca 2 + homeostasis, for the treatment of AD. Further studies are important and urgent to test this class of drug in AD patients.
Although long-term treatment of dantrolene in aged 3XTg-AD mice significantly decreased presympotomatic intraneuronal amyloid load, this study is limited by the difficulty in evaluating the possible therapeutic effects of dantrolene on cognitive dysfunction due to the lack of obvious memory or learning impairment in these aged AD mice. It will be important to investigate the possible therapeutic role of dantrolene treatment in ameliorating cognitive dysfunction in a more aggressive AD animal model in the future. Particularly, future studies need to investigate whether dantrolene can be a drug to stop the progression of cognitive dysfunction in AD, not just relieve symptoms. The treatment of frank AD has not been effective thus far and the field is moving toward treatment during the premild cognitive impairment (pre-MCI) stage. Pre-MCI is primarily characterized by reduced hippocampal volume and amyloid-beta accumulation, well before the onset of behavioral symptoms. 36 Although it is difficult to predict pre-MCI in humans, 3xTg-AD mice eventually acquire the AD phenotype and is thus as a good model of an AD vulnerable brain. The prolonged progression and delay in the AD phenotype, which we see here, is a good model of pre-MCI. Although the delay in the disease progression in our 3xTg-AD mice may be related to genetic drift toward the background strains, we find that it just takes longer than expected with each generation to develop the AD phenotype. However, the significant appearance of positive 6E10 and AT180 cells in the hippocampus CA1 (Figs. 2, 3 ) argues against significant gene drift in our 3xTg-AD mice.
Although a previous study demonstrated the aggravating effects of dantrolene on amyloid pathology, neurodegeneration, and synapse damage in AD mice, 22 several recent studies 9-11 consistently showed the beneficial effects of dantrolene to ameliorate memory loss and associated reduction of amyloid burden in various transgenic AD mice. These recent reports 9-11 are significant and are encouraging for further studies on dantrolene therapy for AD, especially for our mild cognitively impaired and AD patients. Considerable experience has been accumulated on the clinical use of dantrolene to treat other disorders, such as malignant hyperthermia, muscle spasm, and neuroleptic malignant syndrome. 14 The few side effects from the chronic use of dantrolene including drowsy and sleepy, weakness, etc., and are relatively tolerable in patients. 14 Likewise, our aged mice showed no motor or other side effects from 6 months treatment with dantrolene. Should the efficacy of dantrolene treatment for AD be proven, it could be implemented in AD patients quickly.
The neuroprotective effects of dantrolene are clearly dose dependent in in vitro and in vivo models. 14, 17, 37 There has been controversy as to whether or not dantrolene can easily pass through the blood brain barrier. Our studies, 10, 17 together with others, 15 suggested that dantrolene passed the BBB to a limited degree. Therefore, an important strategy to improve dantrolene treatment in AD in the future will be to increase its concentration in the brain while decreasing its concentration in the periphery to maximize its effects on the brain and minimize any side effects. Another strategy to improve drug therapy for AD will be to develop new drugs that selectively inhibit ryanodine receptors and easily get into the brain, without significant peripheral side effects.
MRI has been increasingly used in AD mice as a new research tool considering its advantage of noninvasiveness and repeated in vivo measures to monitor the progress of neuropathology. 38 MRI has been used to measure in vivo changes of brain volume, 39 amyloid load, 40 white matter. 41 Cognitive dysfunction in AD mice seems to be closely associated to the volume of the hippocampus. 39 Hippocampal and cortical volumes can be clearly viewed and accurately measured by the MRI technique in this study (Fig. 4 ). We did not detect amyloid plaques in the different brain regions, consistent with the absence of extracellular plaques in the brain by immunohistochemistry. The brain volume, especially in the hippocampal formation, has been demonstrated to be either decreased 42 or increased 43 in AD patients. The decrease in hippocampal volume may be caused by neurodegeneration, whereas an increase in the brain volume is presumably due to progressive gliosis and amyloidosis. 43 The lack of amyloid plaque and changes in hippocampus volume determined by MRI in the aged 3xTg-AD mice in the current study correlated to the absence of cognitive dysfunction, suggesting that these aged 3xTg-AD mice are still presymptomatic, despite the significant increase in intraneuronal amyloid accumulation and slight elevation of phosphorylated tau protein. Our results suggest that MRI is a useful tool to monitor the dynamic changes of neuropathology in the brain of AD mice
In summary, long-term treatment with dantrolene for presymptomatic AD is effective for the reduction in the accumulation of intraneuronal amyloid and may be a potential therapeutic treatment for preclinical AD.
